Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–64. https://doi.org/10.1172/JCI23409.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallek M, Information CME. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–60. https://doi.org/10.1002/ajh.00046.

Article  CAS  PubMed  Google Scholar 

Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, et al. Identification of a global gene expression signature of B‑chronic lymphocytic leukemia. Mol Cancer Res. 2003;1:346–61.

CAS  PubMed  Google Scholar 

Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Memarian A, Hojjat-Farsangi M, Asgarian-Omran H, Younesi V, Jeddi-Tehrani M, Sharifian RA, et al. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:2061–70. https://doi.org/10.3109/10428190903331082.

Article  CAS  PubMed  Google Scholar 

Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, et al. Somatic mutation as a mechanism of Wnt/beta-catenin pathway activation in CLL. Blood. 2014;124:1089–98. https://doi.org/10.1182/blood-2014-01-552067.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50. https://doi.org/10.1038/nrc2764.

Article  CAS  PubMed  Google Scholar 

Gutierrez AJ, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, et al. LEF‑1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B‑cell lymphocytosis. Blood. 2010;116:2975–83. https://doi.org/10.1182/blood-2010-02-269878.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Br J Haematol. 2016;175:851–9. https://doi.org/10.1111/bjh.14312.

Article  CAS  PubMed  Google Scholar 

MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9–26. https://doi.org/10.1016/j.devcel.2009.06.016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. https://doi.org/10.1038/nature03319.

Article  CAS  PubMed  Google Scholar 

Gandhirajan RK, Staib PA, Minke K, Gehrke I, Plickert G, Schlösser A, et al. Small molecule inhibitors of Wnt/beta-catenin/lef‑1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia. 2010;12:326–35. https://doi.org/10.1593/neo.91972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menter T, Dirnhofer S, Tzankov A. LEF1: a highly speci fi c marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. J Clin Pathol. 2015;68(6):473–8. https://doi.org/10.1136/jclinpath-2015-202862.

Article  CAS  PubMed  Google Scholar 

Wu W, Zhu H, Fu Y, Shen W, Miao K, Hong M, et al. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid. Oncotarget. 2016;7:21631–43. https://doi.org/10.18632/oncotarget.7795.

Article  PubMed  PubMed Central  Google Scholar 

Skokowa J, Welte K. LEF‑1 is a decisive transcription factor in neutrophil granulopoiesis. Ann N Y Acad Sci. 2007;1106:143–51. https://doi.org/10.1196/annals.1392.012.

Article  CAS  PubMed  Google Scholar 

Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, Nusse R, et al. Wnt signaling regulates B lymphocyte proliferation through a LEF‑1 dependent mechanism. Immunity. 2000;13:15–24. https://doi.org/10.1016/s1074-7613(00)00004-2.

Article  CAS  PubMed  Google Scholar 

Metzeler KH, Heilmeier B, Edmaier KE, Rawat VPS, Dufour A, Dohner K, et al. High expression of lymphoid enhancer-binding factor‑1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood. 2012;120:2118–26. https://doi.org/10.1182/blood-2012-02-411827.

Article  CAS  PubMed  Google Scholar 

Elbaiomy MA, Aref S, El Zaafarany M, Atwa S, Akl T, El-Beshbishi W, et al. Prognostic impact of lymphoid enhancer factor 1 expression and serum Galectin.3 in Egyptian AML patients. Adv Hematol. 2019;2019:2352919. https://doi.org/10.1155/2019/2352919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aly RM, Yousef AB. Prognostic significance of lymphoid enhancer-binding factor‑1 expression in egyptian adult B‑acute lymphocytic leukemia patients. Turk J Haematol. 2015;32:15–20. https://doi.org/10.4274/tjh.2013.0140.

Article  PubMed  PubMed Central  Google Scholar 

Kuhnl A, Gokbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B‑precursor acute lymphoblastic leukemia. Blood. 2011;118:6362–7. https://doi.org/10.1182/blood-2011-04-350850.

Article  CAS  PubMed  Google Scholar 

Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, et al. Inactivation of LEF1 in T‑cell acute lymphoblastic leukemia. Blood. 2010;115:2845–51. https://doi.org/10.1182/blood-2009-07-234377.

Article  PubMed  PubMed Central  Google Scholar 

Erdfelder F, Hertweck M, Filipovich A, Uhrmacher S, Kreuzer KA. High lymphoid enhancer-binding factor expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia. Hematol Rep. 2010;2:24–7. https://doi.org/10.4081/hr.2010.e3.

Article  CAS  Google Scholar 

Spaulding C, Reschly EJ, Zagort DE, Yashiro-Ohtani Y, Beverly LJ, Capobianco A, et al. Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T‑cell lymphomas. Blood. 2007;110:2650–8. https://doi.org/10.1182/blood-2007-04-084202.

Article  CAS  PubMed  Google Scholar 

McCarthy BA, Yancopoulos S, Tipping M, Yan X‑J, Wang XP, Bennett F, et al. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res. 2015;63:90–100. https://doi.org/10.1007/s12026-015-8688-3.

Article  CAS  PubMed  Google Scholar 

Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:3118–23. https://doi.org/10.1073/pnas.0308648100.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/β-catenin pathway. PLoS One. 2009;4(12):e8294. https://doi.org/10.1371/journal.pone.0008294.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thanendrarajan S, Kim Y, Schmidt-Wolf IGH. Understanding and targeting the Wnt/β-catenin signaling pathway in chronic leukemia. Leuk Res Treatment. 2011;2011:1–7. https://doi.org/10.4061/2011/329572.

Article  CAS  Google Scholar 

Petrini M, Conte A, Caracciolo F, Sabbatini A, Grassi B, Ronca G. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol. 1993;85:409–10. https://doi.org/10.1111/j.1365-2141.1993.tb03187.x.

Article  CAS  PubMed  Google Scholar 

Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011;108:13253–7. https://doi.org/10.1073/pnas.1110431108.

Article  PubMed  PubMed Central  Google Scholar 

Razavi R, Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M, Kreuzer KA. Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 2011;17:286–93. https://doi.org/10.1158/1078-0432.CCR-10-1030.

Article  CAS  PubMed